# AbCellera Biologics Inc. (ABCL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.43, market value $3.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). AbCellera Biologics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 56.0×**. Each dollar of revenue is priced at 56.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.9×**. The shares trade at 3.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -3.2%** (5-yr avg -7.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -340.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -194.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -15.1%**. Return on equity is negative because earnings are negative.
- **Return on assets: -12.1%**. Each dollar of assets produces -12.1% of profit.

## Growth
- **Revenue growth (1 yr): 160.6%** (3-yr -46.3%/yr, 5-yr -20.3%/yr). Revenue grew 160.6% over the last year, against -20.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 10.9%**. Earnings per share rose 10.9%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 11.32** (quick 11.32). Current assets cover the next year's liabilities 11.32 times.
- **Altman Z-score: 6.81**. A Z-score of 6.81 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. AbCellera Biologics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 174.8%** (YTD 234.2%, 3-mo 103.4%). The shares are up 174.8% over twelve months including dividends.
- **From 52-week high: -9.1%** (316.4% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 2.59** (volatility 87%). Beta of 2.59 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABCL · Page: https://foliofundamentals.com/stocks/abcl

Not investment advice.